Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Lenz Therapeutics develops innovative ophthalmic therapies, focusing on presbyopia. Its lead product, LNZ100, is a once-daily, aceclidine-based eye drop designed to improve near vision safely and effectively for a broad age range. The company aims to become a category leader by leveraging proprietary technology, pursuing FDA approval, and building a specialized commercial team to serve presbyopes globally.
This description was generated via AI from an annual report. Updated about 1 year ago.